Author Affiliations: Larry L. Hillblom Islet Research Center (Drs Gier and Butler) and Jonsson Comprehensive Cancer Center (Dr Butler), University of California, Los Angeles, David Geffen School of Medicine.
The worldwide prevalence of type 2 diabetes mellitus (T2DM) is approaching 100 million.1 Most affected individuals are treated for decades. Not surprisingly, the market for drug treatment of T2DM is worth more than $20 billion per year. The most lucrative drugs are those still protected by patent and deemed worthy of selection despite high expense because of clear advantages over cheaper drugs no longer covered by patent protection.
Gier B, Butler PC. Glucagonlike Peptide 1–Based Drugs and Pancreatitis: Clarity at Last, but What About Pancreatic Cancer?Comment on “Glucagonlike Peptide 1–Based Therapies and Risk of Hospitalization for Acute Pancreatitis in Type 2 Diabetes Mellitus”. JAMA Intern Med. 2013;173(7):539-541. doi:10.1001/jamainternmed.2013.3374